Hancock Whitney Corp Arcus Biosciences, Inc. Transaction History

Hancock Whitney Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 13, 2023	SELL	$15.96 - $23.15 $12,624 - $18,311	-791 Reduced 6.21%	11,945 $217,000
Q1 2023 May 16, 2023	SELL	$15.96 - $23.15 $12,624 - $18,311	-791 Reduced 6.21%	11,945 $218,000
Q4 2022 Nov 13, 2023	BUY	$19.7 - $35.71 $250,899 - $454,802	12,736 New	12,736 $263,000
Q4 2022 Feb 03, 2023	BUY	$19.7 - $35.71 $250,899 - $454,802	12,736 New	12,736 $263,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

Stay updated on Hancock Whitney Corp with notifications on news.